Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634452 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
A Phase 1 study of Hodgkin's Lymphomas, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT00634452: Completed Phase 1 study of Hodgkin's Lymphomas, sponsored by Bristol-Myers Squibb.
NCT00634452 is a Phase 1 study of Hodgkin's Lymphomas that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634452, a Phase 1 study of Hodgkin's Lymphomas, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
Conditions Studied
Interventions
- BIOLOGICAL MDX-1401
Study Locations (6)
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- ClinWorks Cancer Research Center - Charlotte
Texas
- Scott and White Memorial Hospital and Clinic - Temple
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00634452 record still lists
NCT00634452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Hodgkin's Lymphomas appearing as the primary indexed condition, and to 1 intervention - of which MDX-1401 is the first listed.
NCT00634452 lists 6 locations in 6 states (Georgia, Illinois, New York).
Frequently Asked Questions
What is clinical trial NCT00634452 about?
NCT00634452 is a clinical study titled "Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma". To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
What is the current status of trial NCT00634452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-02. Estimated completion is 2010-01.
What conditions does trial NCT00634452 study?
This clinical trial studies the following conditions: Hodgkin's Lymphomas.
What interventions are being tested in trial NCT00634452?
The interventions under investigation include: MDX-1401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00634452?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634452 being conducted?
This trial has 6 study locations across Georgia, Illinois, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00634452's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia